Scar - Pipeline Review, H1 2018

  • ID: 4473107
  • Report
  • 84 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Abzena Plc
  • Altacor Ltd
  • BirchBioMed Inc
  • Clanotech AB
  • Escape Therapeutics Inc
  • Kringle Pharma Inc
  • MORE
Scar - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Scar - Pipeline Review, H1 2018, provides an overview of the Scar (Dermatology) pipeline landscape.

A scar is a permanent patch of skin that grows over a wound. Scars occur at the site of tissue damage and appear as firm red to purple fibrous tissue that over time usually becomes flatter and lighter in color.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Scar - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Scar (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Scar (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Scar and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 5, 2 and 12 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Scar (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Scar (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Scar (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Scar (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Scar (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Scar (Dermatology)
Reasons to Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Scar (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Scar (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abzena Plc
  • Altacor Ltd
  • BirchBioMed Inc
  • Clanotech AB
  • Escape Therapeutics Inc
  • Kringle Pharma Inc
  • MORE
Introduction

Report Coverage

Scar - Overview

Scar - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Scar - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Scar - Companies Involved in Therapeutics Development

Abzena Plc

Altacor Ltd

BirchBioMed Inc

Clanotech AB

Cotinga Pharmaceuticals Inc

Escape Therapeutics Inc

Kringle Pharma Inc

Pharmaxis Ltd

Promore Pharma

RXi Pharmaceuticals Corp

Synedgen Inc

Vascular BioSciences

Scar - Drug Profiles

albuterol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BTL-slo - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLT-28643 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

decorin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EB-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FibroStem - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FS-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein for Scar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICX-RHY - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-100IT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

magacizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MG-53 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MMI-0100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Fibrotic Scar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nefopam hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polysaccharide for Wounds and Scars - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXL-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXI-109 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Lysyl Oxidase for Scar and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit SOX-9 for Scar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Antagonize TGF-Beta Receptor Type 1 and 2 for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tranilast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Scar - Dormant Projects

Scar - Discontinued Products

Scar - Product Development Milestones

Featured News & Press Releases

Feb 16, 2018: BirchBioMed is cleared to begin first-of-its-kind phase II clinical trial for ground-breaking anti-scarring drug

Feb 15, 2018: Promore Pharma Regains Rights for PXL01 Manufacturing

Feb 08, 2018: Bonti Announces Dosing of the First Patient in the SHINE-1 Phase 2 Clinical Study Evaluating EB-001 for Scar Reduction

Feb 01, 2018: Promore Pharma is granted a patent for PXL01 in the US

Jan 02, 2018: Promore Pharma Adjusts Plans for PXL01 in North America

Dec 18, 2017: RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with RXI-109 for Dermal Scarring

Jun 27, 2017: ScarX Achieves Full Enrollment in Human Scar Reduction Trial Safety and Efficacy Results Targeted for Late 2

May 17, 2017: Promore Pharma files phase III clinical trial application in India

Mar 28, 2017: RXi Pharmaceuticals Granted Patent in Japan for Lead Clinical Candidate RXI-

Aug 25, 2016: BirchBioMed announces completion of clinical trial for ground-breaking anti-scarring drug

Aug 18, 2016: ScarX announces approval for trial of first clinically-promising scar reduction cream

Apr 28, 2016: RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model

Apr 25, 2016: RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference

Apr 19, 2016: RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-

Mar 31, 2016: Rxi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Scar, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Scar - Pipeline by Abzena Plc, H1 2018

Scar - Pipeline by Altacor Ltd, H1 2018

Scar - Pipeline by BirchBioMed Inc, H1 2018

Scar - Pipeline by Clanotech AB, H1 2018

Scar - Pipeline by Cotinga Pharmaceuticals Inc, H1 2018

Scar - Pipeline by Escape Therapeutics Inc, H1 2018

Scar - Pipeline by Kringle Pharma Inc, H1 2018

Scar - Pipeline by Pharmaxis Ltd, H1 2018

Scar - Pipeline by Promore Pharma, H1 2018

Scar - Pipeline by RXi Pharmaceuticals Corp, H1 2018

Scar - Pipeline by Synedgen Inc, H1 2018

Scar - Pipeline by Vascular BioSciences, H1 2018

Scar - Dormant Projects, H1 2018

Scar - Discontinued Products, H1 2018

List of Figures:

Number of Products under Development for Scar, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abzena Plc
  • Altacor Ltd
  • BirchBioMed Inc
  • Clanotech AB
  • Cotinga Pharmaceuticals Inc
  • Escape Therapeutics Inc
  • Kringle Pharma Inc
  • Pharmaxis Ltd
  • Promore Pharma
  • RXi Pharmaceuticals Corp
  • Synedgen Inc
  • Vascular BioSciences
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll